Shots:

• The approval is based on COAPT study assessing MitraClip + medical therapy vs medical therapy as monothx. in 614 patients with moderate to severe secondary MR across 78sites including the US & Canada
• The COAPT study resulted in meting its 1EPs & 10 2EPs with the reduction in hospitalization & mortality 47% & 38% respectively
• Abbott’s MitraClip is a novel transcatheter clip-based mitral valve intervention therapy & has received FDA’s approval in 2013 for reducing mitral regurgitation

Ref: Abbott | Image: Abbott